Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Market Analysis and Insights: Global Nuclear Medicine/Radiopharmaceutic Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Nuclear Medicine/Radiopharmaceutic market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Nuclear Medicine/Radiopharmaceutic industry.
Based on our recent survey, we have several different scenarios about the Nuclear Medicine/Radiopharmaceutic YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Nuclear Medicine/Radiopharmaceutic will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Nuclear Medicine/Radiopharmaceutic Scope and Market Size
Nuclear Medicine/Radiopharmaceutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Nuclear Medicine/Radiopharmaceutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Nuclear Medicine/Radiopharmaceutic market is segmented into
Tc-99
I-123/131
In-111
Xe-133
Th-201
Ga-67
Other
Segment by Application, the Nuclear Medicine/Radiopharmaceutic market is segmented into
Diagnostic
Therapeutic
Regional and Country-level Analysis
The Nuclear Medicine/Radiopharmaceutic market is analysed and market size information is provided by regions (countries).
The key regions covered in the Nuclear Medicine/Radiopharmaceutic market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Nuclear Medicine/Radiopharmaceutic market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Nuclear Medicine/Radiopharmaceutic business, the date to enter into the Nuclear Medicine/Radiopharmaceutic market, Nuclear Medicine/Radiopharmaceutic product introduction, recent developments, etc.
The major vendors covered:
GE Healthcare
Bracco Imaging
Mallinckrodt
Lantheus Medical Imaging
Bayer
Jubilant Pharma
Nordion
Eli Lilly
SIEMENS
China Isotope & Radiation
Yantai Dongcheng Biochemicals
Market Analysis and Insights: Global Nuclear Medicine/Radiopharmaceutic Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Nuclear Medicine/Radiopharmaceutic market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Nuclear Medicine/Radiopharmaceutic industry.
Based on our recent survey, we have several different scenarios about the Nuclear Medicine/Radiopharmaceutic YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Nuclear Medicine/Radiopharmaceutic will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Nuclear Medicine/Radiopharmaceutic Scope and Market Size
Nuclear Medicine/Radiopharmaceutic market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Nuclear Medicine/Radiopharmaceutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Nuclear Medicine/Radiopharmaceutic market is segmented into
Tc-99
I-123/131
In-111
Xe-133
Th-201
Ga-67
Other
Segment by Application, the Nuclear Medicine/Radiopharmaceutic market is segmented into
Diagnostic
Therapeutic
Regional and Country-level Analysis
The Nuclear Medicine/Radiopharmaceutic market is analysed and market size information is provided by regions (countries).
The key regions covered in the Nuclear Medicine/Radiopharmaceutic market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Nuclear Medicine/Radiopharmaceutic Market Share AnalysisNuclear Medicine/Radiopharmaceutic market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Nuclear Medicine/Radiopharmaceutic business, the date to enter into the Nuclear Medicine/Radiopharmaceutic market, Nuclear Medicine/Radiopharmaceutic product introduction, recent developments, etc.
The major vendors covered:
GE Healthcare
Bracco Imaging
Mallinckrodt
Lantheus Medical Imaging
Bayer
Jubilant Pharma
Nordion
Eli Lilly
SIEMENS
China Isotope & Radiation
Yantai Dongcheng Biochemicals
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
